Kyle Bass Ampyra IPR challenge is ‘harassment’, says Acorda
16-12-2015
Acorda hits back at Kyle Bass IPR
28-05-2015
Gustavo Frazao / Shutterstock.com
The Patent Trial and Appeal Board (PTAB) has instituted trials on four patents owned by Acorda Therapeutics following challenges from the Coalition for Affordable Drugs and hedge fund manager Kyle Bass.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Patent Trial and Appeal Board; USPTO; PTAB; US Patent and Trademark Office; Kyle Bass; Coalition for Affordable Drugs; obvious; Acorda; Ampyra
